The effect of emavusertib on tumor growth was evaluated in vivo in the subcutaneous MV4-11 and MOLM-14 AML tumor models which harbor FLT3-ITD mutations and are sensitive to FLT3 inhibitors in cell-based assays and subcutaneous tumor xenograft model studies (71). The gene discussed is FLT3; the disease is acute myeloid leukemia.